Vidac Pharma Holding PLC: Invitation to 17th International Investment Forum (IIF) on December 3rd, 2025

London (pta018/27.11.2025/11:41 UTC+1)

London (UK), November 27th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced that it has been invited to present at the 17th International Investment Forum (IIF), to be held on December 3rd, 2025.

The Company's Chief Executive Officer, Dr. Max Herzberg, will deliver a comprehensive presentation highlighting Vidac's clinical progress, strategic roadmap, and upcoming milestones. The IIF is a global platform that provides insights into investment trends and ideas across a broad range of industries, featuring top executives, managers, and decision-makers from around the world.

Vidac's invitation to the IIF reflects the growing global interest in the Company's pioneering approach to targeting cancer metabolism and advancing first-in-class therapeutics. Dr. Herzberg will present Vidac's advancements in oncology, updates on its clinical programs, and the Company's vision for 2026 and beyond.

Dr. Max Herzberg, CEO of Vidac Pharma, commented:
"Vidac Pharma is honored to be invited to present at the 17th International Investment Forum. This global platform brings together top-tier investors and industry leaders, and we look forward to sharing Vidac's scientific progress and future direction as we continue advancing our mission of transforming cancer treatment through metabolic reprogramming."

For more information please contact:
Vidac Pharma Holding Plc
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase-2 metabolic checkpoint (HK2) in cancer cells to renormalize the tumor microenvironment and selectively provoke programmed cell death without affecting surrounding normal tissue. VDA-1102, Vidac Pharma's first drug candidate, has demonstrated effectiveness against advanced Actinic Keratosis (AK), while interim Phase 2 results in Cutaneous T-Cell Lymphoma (CTCL) have shown promising clinical benefit in humans.

Important Information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding Plc, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "may," "will," "plans," "continue," "ongoing," "potential," "predict," "project," "target," "seek," or "should," and include statements the Company makes concerning the intended results of its strategy.
By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Hamburg, Stuttgart